Omeros announces online publication in advance of ash annual meeting detailing narsoplimab treatment under compassionate use of 15 patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (ta-tma), 14 of whom had “high-risk” ta-tma. narsoplimab is omeros' investigational antibody targeting masp-2, the effector enzyme of the lectin pathway of the complement system. the report was authored by an external group of investigators i.
OMER Ratings Summary
OMER Quant Ranking